Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N Engl J Med. 2001;344:783–92.

Article  CAS  PubMed  Google Scholar 

Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, et al. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study. J Clin Oncol. 2020;38:1887–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med. 2012;367:1783–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet Lond Engl. 2023;401:105–17.

Article  CAS  Google Scholar 

Gullo G, Zuradelli M, Sclafani F, Santoro A, Crown J. Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2012;23:2204–5.

Article  CAS  Google Scholar 

Gámez-Pozo A, Carrión RMP, Manso L, Crespo C, Mendiola C, López-Vacas R, et al. The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+ Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy. PLOS ONE. 2014;9:e109611.

Article  PubMed  PubMed Central  Google Scholar 

Harano K, Lei X, Gonzalez-Angulo AM, Murthy RK, Valero V, Mittendorf EA, et al. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2016;159:367–74.

Article  CAS  PubMed  Google Scholar 

Murthy P, Kidwell KM, Schott AF, Merajver SD, Griggs JJ, Smerage JD, et al. Clinical predictors of long-term survival in HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2016;155:589–95.

Article  PubMed  PubMed Central  Google Scholar 

Wong Y, Raghavendra AS, Hatzis C, Irizarry JP, Vega T, Horowitz N, et al. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy. The Oncologist. 2019;24:313–8.

Article  CAS  PubMed  Google Scholar 

Kaczmarek E, Saint-Martin C, Pierga JY, Brain E, Rouzier R, Savignoni A, et al. Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the French real-life curie database. Breast Cancer Res Treat. 2019;178:505–12.

Article  CAS  PubMed  Google Scholar 

Walsh N, Andrieu C, O’Donovan P, Quinn C, Maguire A, Furney SJ, et al. Whole-exome sequencing of long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer. Br J Cancer. 2020;123:1219–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang DK, Grimmond SM, Evans TRJ, Biankin AV. Mining the genomes of exceptional responders. Nat Rev Cancer. 2014;14:291–2.

Article  CAS  PubMed  Google Scholar 

Wheeler DA, Takebe N, Hinoue T, Hoadley KA, Cardenas MF, Hamilton AM, et al. Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. Cancer Cell. 2021;39:38–53.e7.

Article  CAS  PubMed  Google Scholar 

Lim SM, Kim E, Jung KH, Kim S, Koo JS, Kim SI, et al. Genomic landscape of extraordinary responses in metastatic breast cancer. Commun Biol. 2021;4:449.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Joshi NA, Fass JN. Sickle: A sliding-window, adaptive, quality-based trimming tool for FastQ files (Version 1.33) [Software] 2011. Available from: https://github.com/najoshi/sickle

Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics. 2009;25:1754–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297–303.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tarasov A, Vilella AJ, Cuppen E, Nijman IJ, Prins P. Sambamba: fast processing of NGS alignment formats. Bioinformatics. 2015;31:2032–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pedersen BS, Quinlan AR. Mosdepth: quick coverage calculation for genomes and exomes. Bioinformatics. 2018;34:867–8.

Article  CAS  PubMed  Google Scholar 

Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, et al. Twelve years of SAMtools and BCFtools. GigaScience. 2021;10:giab008.

Article  PubMed  PubMed Central  Google Scholar 

Boeva V, Popova T, Bleakley K, Chiche P, Cappo J, Schleiermacher G, et al. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics. 2012;28:423–5.

Article  CAS  PubMed  Google Scholar 

Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. PLOS Comput Biol. 2016;12:e1004873.

Article  PubMed  PubMed Central  Google Scholar 

Pruitt KD, Tatusova T, Maglott DR. NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res. 2007;35:D61–5.

Article  CAS  PubMed  Google Scholar 

Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26:841–2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Graham E, Rampazzo L, Leung CWB, Wall J, Gerőcz EZ, Liskovykh M, et al. The homologous recombination factors BRCA2 and PALB2 interplay with mismatch repair pathways to maintain centromere stability and cell viability. Cell Rep. 2025;44:115259.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Showman S, Talbert PB, Xu Y, Adeyemi RO, Henikoff S. Expansion of human centromeric arrays in cells undergoing break-induced replication. Cell Rep. 2024;43:113851.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Contreras-Galindo R, Fischer S, Saha AK, Lundy JD, Cervantes PW, Mourad M, et al. Rapid molecular assays to study human centromere genomics. Genome Res. 2017;27:2040–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hieronymus H, Schultz N, Gopalan A, Carver BS, Chang MT, Xiao Y, et al. Copy number alteration burden predicts prostate cancer relapse. Proc Natl Acad Sci. 2014;111:11139–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hieronymus H, Murali R, Tin A, Yadav K, Abida W, Moller H, et al. Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. Green MR, Settleman J, Abate-Shen C, Rubin MA, editors. eLife. 2018;7:e37294.

de Lima